Paramethadione

Paramethadione
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Pharmacokinetic data
Protein bindingNot significant
Identifiers
  • (RS)-5-Ethyl-3,5-dimethyl-oxazolidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.003.726 Edit this at Wikidata
Chemical and physical data
FormulaC7H11NO3
Molar mass157.169 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C1N(C(=O)OC1(C)CC)C
  • InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3 checkY
  • Key:VQASKUSHBVDKGU-UHFFFAOYSA-N checkY
  (verify)

Paramethadione (brand name Paradione) is an anticonvulsant drug of the chemical class called oxazolidinediones developed by the Illinois-based pharmaceutical company Abbott Laboratories (known as AbbVie since January 1, 2013 [1]), and approved by the Food and Drug Administration in 1949 for the treatment of absence seizures, also called partial seizures.[2][3]

In 1960, the yearly cost for 900 mg/day paramethadione was approximately $66,[4] which would translate to $462 yearly in 2007 (with CPI inflation) if paramethadione was still sold.[5]

  1. ^ More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie - Retrieved November 7, 2016
  2. ^ "Oxazolidinedione Anticonvulsants". drugs.com.
  3. ^ Sittig M (2015). Pharmaceutical manufacturing encyclopedia. New York: William Andrew Pub.
  4. ^ Lennox WG (1960). Epilepsy and related disorders. Boston: Little Brown.
  5. ^ Shorvon SD (March 2009). "Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009". Epilepsia. 50 Suppl 3 (s3): 93–130. doi:10.1111/j.1528-1167.2009.02042.x. PMID 19298435.